Education
About Us
Working with TipRanks
Follow Us
Theratechnologies (TSE:TH)
:TH
Top Page
Theratechnologies
(TH)
Select Model
Select Model
Rating:61Neutral
Price Target:
$4.50
Theratechnologies' overall score is driven by positive corporate events, including a favorable acquisition agreement, which boosts shareholder value. Strong technical indicators also support the stock's outlook. However, financial performance and valuation challenges, such as negative equity and a lack of profitability, weigh on the score.
Theratechnologies (TH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)N/A
Revenue Growth5.24%
EPS Growth-7.99%
CountryCA
EmployeesN/A
SectorN/A
Sector StrengthN/A
IndustryN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Theratechnologies Business Overview & Revenue Model
Company DescriptionTheratechnologies Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions. The company primarily operates in the biotechnology sector, specializing in the research and development of treatments for metabolic and endocrine disorders, with a particular emphasis on human immunodeficiency virus (HIV) and growth hormone deficiencies. Its core product, Trogarzo (ibalizumab-uiyk), is a monoclonal antibody approved for the treatment of HIV-1 in heavily treatment-experienced patients, highlighting the company's commitment to addressing unmet medical needs in complex patient populations.
How the Company Makes MoneyTheratechnologies generates revenue primarily through the sale of its pharmaceutical products, notably Trogarzo, which is marketed to healthcare providers and institutions treating HIV patients. The company also engages in strategic partnerships and collaborations with other pharmaceutical companies to co-develop therapies and share in the financial benefits of new product launches. Additionally, Theratechnologies may receive milestone payments and royalties from its partners based on the performance of co-developed products. The company's revenue model is bolstered by its focus on niche markets within the biopharmaceutical sector, allowing for higher pricing power and specialized marketing efforts.
Theratechnologies Earnings Call Summary
Earnings Call Date:Apr 09, 2025
(Q1-2025)
| Next Earnings Date:Oct 09, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth and recovery post-drug shortage, along with positive R&D developments. However, challenges such as the previous drug shortage's financial impact and declining Trogarzo sales indicate a cautious business outlook.Q1-2025 Updates
Positive Updates
Revenue Growth
Total revenues increased to $19 million, representing a 17% growth from the previous year, driven by strong performance of EGRIFTA SV.
EGRIFTA SV Recovery and Transition Plan
Following a drug shortage, EGRIFTA SV resumed distribution, with new enrollments up 15% in Q1 compared to last year. The transition to the new F8 formulation is planned for completion by early 2026.
Positive Adjusted EBITDA
The company reported a positive adjusted EBITDA of $2.3 million, up from a loss of $247,000 last year.
New Formulation Approval
Approval of the F8 Formulation of Tesamorelin, which requires less frequent reconstitution and is expected to improve patient adherence and experience.
Research and Development Progress
Data from the PROMISE-U.S. and VAMOS studies presented, highlighting the efficacy and safety of ibalizumab and the importance of EVAF in cardiovascular risk assessment in HIV patients.
Negative Updates
Impact of Drug Shortage
The drug shortage resulted in a sales loss of six to seven weeks, translating to approximately $10 million in lost revenue.
Decline in Trogarzo Sales
Trogarzo sales decreased by 22% due to new competitors and patient loss, despite some stabilization in enrollments.
Guidance for 2025
Revised guidance for 2025 with expected revenues of $80 million to $83 million and adjusted EBITDA of $10 million to $12 million, indicating a cautious outlook.
Company Guidance
During the Theratechnologies First Quarter 2025 Earnings Call, the company provided guidance for the fiscal year, projecting total revenues of $80 to $83 million and an adjusted EBITDA of $10 to $12 million. Despite a temporary drug shortage impacting EGRIFTA SV sales for six to seven weeks, the company reported $19 million in total revenues for the quarter, marking a 17% increase year-over-year. Adjusted EBITDA for the quarter was $2.3 million, compared to a loss of $247,000 in the previous year. The company also discussed the successful rebound in patient enrollments, which were up 15% in the first quarter compared to last year. Additionally, they highlighted the recent approval of the F8 Formulation of Tesamorelin and the anticipated transition from EGRIFTA SV to EGRIFTA WR, expected to be completed by early 2026.Theratechnologies Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Theratechnologies Technical Analysis
Neutral
―
Price Trends
4.48
Negative
4.11
Positive
3.40
Positive
Market Momentum
<0.01
Positive
45.96
Neutral
29.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 4.54, equal to the 50-day MA of 4.48, and equal to the 200-day MA of 3.40, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.96 is Neutral, neither overbought nor oversold. The STOCH value of 29.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:TH.
Theratechnologies Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― |
* Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.